Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: OPC 31260; Physuline

Latest Information Update: 08 Sep 2011

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Otsuka Pharmaceutical
  • Class Antihypertensives; Benzazepines; Cardiotonics
  • Mechanism of Action Vasopressin V2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyponatraemia

Highest Development Phases

  • Marketed Hyponatraemia
  • Discontinued Hypertension; Polycystic kidney disease; Postmyocardial infarction

Most Recent Events

  • 21 Apr 2006 Preregistration for Hyponatraemia in Japan (unspecified route)
  • 21 Jan 2003 OPC 31260 is now called Mozavaptan
  • 11 Jan 2000 A preclinical study has been added to the Genitourinary Disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top